ArticleJAC-antimicrobial resistance2026
Genetic and clinical landscape of methicillin-resistant
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Penicillin-Binding Protein-4 (PBP4) ofMicroorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The present study examines methicillin-resistant Methods: Between October 2021 and February 2023, 13 MRLM isolates were identified among 867 Results: Ten of the 13 MRLMs were resistant to cefoxitin (MICs >4 mg/L), including two that were also resistant to oxacillin. The remaining three isolates were susceptible to both cefoxitin and oxacillin and exhibited typical growth on CHROMagar MRSA. Seven of the 13 isolates harboured the Conclusions: The importance of accurate differentiation of MRLMs from MRSAs and MSSAs in routine laboratory testing is underscored by our results, which may allow in-depth investigation of the true epidemiology and clinical implications of MRLMs and the actual efficacy of β-lactams against them.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.